Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526299 · ClinicalTrials.gov registry record · Phase 2
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
A Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Castration-resistant Prostate Carcinoma, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 3
- Study locations
NCT06526299 is a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Castration-resistant Prostate Carcinoma that is actively recruiting participants, run by University of Washington. The registered enrollment target is 51 participants, below the 176-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06526299, a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Metastatic Castration-resistant Prostate Carcinoma, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radioactive (tracer) component being delivered by prostate-specific membrane antigen (PSMA)-617, has physical properties that make it ideal radionuclide (imaging tests that uses a small dose tracer) for treatment of metastatic castrate-resistant prostate cancer (mCRPC). 177Lu-PSMA-617 works by binding to prostate cancer cells and inducing damage to deoxyribonucleic acid (DNA) inside prostate cancer cells. Giving 177Lu-PSMA-617 may improve treatment outcomes for patients with mCRPC.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Bone Scan
- DRUG Lutetium Lu 177 Vipivotide Tetraxetan
Study Locations (3)
California
- University of California San Francisco - San Francisco
- Olive View-University of California Los Angeles Medical Center - Sylmar
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06526299
The ClinicalTrials.gov registry entry for NCT06526299 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 176-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (71% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06526299 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Washington.
Frequently Asked Questions
What is clinical trial NCT06526299 about?
NCT06526299 is a clinical study titled "Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease". This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resistant). Lutetium Lu 177 (177Lu), the radioactive (tracer) comp...
What is the current status of trial NCT06526299?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2025-04-29. Estimated completion is 2027-12-31.
What conditions does trial NCT06526299 study?
This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Metastatic Castration-resistant Prostate Carcinoma.
What interventions are being tested in trial NCT06526299?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Bone Scan (PROCEDURE), Lutetium Lu 177 Vipivotide Tetraxetan (DRUG).
Who is sponsoring clinical trial NCT06526299?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526299 being conducted?
This trial has 3 study locations across California, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IVB Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
RECRUITING · Phase 2
-
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
RECRUITING · Phase 2
-
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Stage IVB Prostate Cancer AJCC v8
All registered trials for this condition
Metastatic Castration-resistant Prostate Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.